A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Pritchard
J
J
Department of Clinical Neurosciences, Guy's, King's & St. Thomas' School of Medicine, London, UK.
Gray
I A
IA
Idrissova
Z R
ZR
Lecky
B R F
BR
Sutton
I J
IJ
Swan
A V
AV
Willison
H J
HJ
Winer
J B
JB
Hughes
R A C
RA
D016207:Cytokines / Q000097:blood; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D020275:Guillain-Barre Syndrome / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D011994:Recombinant Proteins; D016899:Interferon-beta; D000068556:Interferon beta-1a